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Summary The interactions of radiation and adriamycin (ADM), bleomycin (BLM), mitomycin C (MM-C),
or cis-diamminedichloroplatinum II (cis-DDP) in mouse jejunal crypt cells were studied using the microcolony
survival assay. ADM administered from 24h before to 48 h after irradiation resulted in an almost constant
enhancement of the radiation response, the dose effect factor (DEF) being 1.19. The effect of BLM was
extremely dependent on the sequence and interval between drug administration and irradiation. The most
pronounced effect was observed when BLM was given 2 h before irradiation (DEF = 2.40), at which interval
the Do surprisingly increased by a factor of 1.4. Administration of MM-C from 24h before to 24h after
irradiation enhanced the radiation response. The effect peaked on administration 6h before irradiation
(DEF = 1.21) and diminished by application after irradiation. Cis-DDP enhanced the radiation response only
when given before irradiation resulting in a DEF of 1.23 and a decreased Do,
The more frequent recourse to combined drug-
radiation regimens in cancer therapy has
unfortunately increased the frequency of unexpected
and unacceptable normal tissue reactions (Muggia
et al., 1978; Peckham & Collis, 1981; Phillips, 1980;
Phillips & Fu, 1976). This may be attributed to our
still limited understanding of the interactions of
radiation and cancer chemotherapeutic agents
which in turn provides the rationale for the conduct
of more experimental studies of this subject.
Attention should especially focus on drug-radiation
interactions in critical normal tissues and the
dependence on the intervals and sequence of the
two treatment modalities.
The intestinal tract mucosa is a critical normal
tissue in which acute radiation effects can be
studied by use of the microcolony survival assay
(Withers & Elkind, 1970). However, the study of the
combined effects of irradiation and cancer
chemotherapeutic drugs requires a modification of
the assay by varying the assay time according to
the effect of the drug on the regeneration time of
the surviving intestinal crypts (von der Maase &
Overgaard, 1983). Thus, the interactions of
radiation and cyclophosphamide, 5-fluorouracil and
methotrexate have previously been investigated (von
der Maase, 1984a). The present study continues
along this line and its purpose was to evaluate the
effect on mouse jejunal crypt cells of adriamycin,
bleomycin, mitomycin C and cis-diamminedichloro-
platinum II administered before, simultaneously
with and after irradiation.
Materials and methods
Unanaesthetized male C3D2F,/Bom mice
(C3H/Tify x DBA/2,S), 9-12 weeks of age, with
good access to air were exposed to single-dose
whole-body irradiation with a 250kV Muller X-ray
unit as previously described (von der Maase,
1984a).
Mitomycin C (MM-C) and cis-diamminedichloro-
platinum II (cis-DDP) were kindly provided by
Bristol-Myers A/S, adriamycin (ADM) by
Farmitalia, Carlo Erba, and bleomycin (BLM) by
H. Lundbeck and Co. A/S. Each drug was applied
at the maximum tolerated dose (MTD), equivalent
to the dose that would kill - 1% of the mice within
60 days. The MTDs were estimated as previously
described (von der Maase, 1984a). BLM was
dissolved in isotonic saline and the other drugs in
sterile distilled water. All drugs were administered
intraperitoneally as single doses at a constant
volume of 0.02mlg1 body wt.
Crypt survival
The crypt number was scored in 2 jejunal cross-
sections per mouse, and all survival curves were
based on 6 mice per dose point (von der Maase &
Overgaard, 1983). Crypt cell survival was
determined according to the method of Withers &
Elkind (1970). In the interval studies the end point
was the number of crypts per circumference without
calculation of the number of crypt cells. All points
in the interval studies and all survival curves were
reproduced at least once.
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The assay times were based on the estimated
regeneration times for each drug-radiation
combination (von der Maase & Overgaard, 1983).
For ADM administered 15min before irradiation
the regeneration time was 102h. When the interval
between ADM and irradiation was increased this
assay time was varied in the same way as described
for previously investigated drug-radiation
combinations (von der Maase, 1984a). Thus, the
assay time for ADM administered 24h before
irradiation diminished to 90h after the radiation
treatment. At administration 72h after irradiation
the assay time was 72h after treatment with ADM,
i.e. in all 144h after irradiation. The assay time for
the other three drug-radiation combinations was
always 90h after the radiation treatment, i.e. the
same as the regeneration time for radiation alone
(von der Maase & Overgaard, 1983).
Statistical analysis and evaluation ofdata
The jejunal crypt cell survival curve characteristics
were calculated by linear regression analysis. The
calculated slope values of these regression lines were
tested for being significantly different from 0
(P<0.001 in all cases). The Do and the calculated
value of surviving cells equivalent to 10Gy
(SC10GY), were used to test for statistically
significant differences by the F-test and Student's t-
test.
The combined drug-radiation effects were
expressed by the dose effect factor (DEF)
DEF = D1o for radiation alone D10 for radiation+drug
D10 being the radiation dose resulting in 10
surviving cells per circumfernece, and by the isodose
effect ratio (IER)




The MTD for single doses of ADM, BLM, MM-C,
and cis-DDP were 8mgkg-', 100mgkg-,
3 mgkg-1, and 6mgkg-1, respectively. Evaluated at
the regeneration time, BLM decreased the crypt
number to about 80-100 per circumference
compared to 135 in untreated controls. The crypt
number was not restored until 14-28 days after
treatment with BLM. The other drugs did not
influence the crypt number scored at the specified
regeneration times.
ADM and irradiation
The effect of ADM given from 72h before to 72h
after 8Gy is shown in Figure 1. Compared with
radiation alone, ADM decreased the crypt number
to an almost constant level by administration from
24h before to 48h after irradiation. The survival
curves for radiation alone and for ADM
administered 15min before irradiation are shown in
Figure 2. ADM did not change the Do whereas the
SCIOGY was significantly decreased compared with
the SC10GY after radiation alone (P<0.001). The
DEF and IER were 1.19 and 5.5, respectively (see
Table I).
BLM and irradiation
BLM was given from 14 days before to 72h after
7Gy. As seen in Figure 3, its influence on the
radiation effect was extremely dependent on the
intervals and sequence of the combined treatment.
Administration of the drug 1-6h before irradiation
had the most pronounced effect which gradually
diminished when the interval was prolonged. In
contrast, administration of BLM after irradiation
enhanced the radiation effect to a much smaller
extent. The curve describing the effect of BLM after
irradiation experienced a sharp drop at 12h and the
effect disappeared at 48h. BLM administered
15min before irradiation statistically significantly
displaced the survival curve to the left (P<0.001)
without changing the Do (Figure 2). The curve was
displaced further to the left when BLM was given
2h before irradiation (Figure 2), which compared
with the 15min interval increased the DEF values
from 1.70 to 2.40 and the IER values from 95 to
139. At the 2h interval the Do was increased by a
factor of 1.4 (see Table I). The difference in the Do
values was statistically significant (P<0.001).
MM-C and irradiation
MM-C was administered from 72h before to 72h
after 9Gy (Figure 4). The radiation response was
enhanced at administration from 24h before to 24h
after irradiation. The effect diminished at
administration after irradiation and indicated a
more pronounced effect on administration 6h
before irradiation. This possibly more pronounced
effect was tested by establishment of survival curves
for MM-C given 15min and 6h before irradiation.
In both cases, the enhanced radiation effect, as
expressed by the SCiOGY, was found to be
statistically significant (P<0.001), and the effect of
MM-C 6h before irradiation increased significantly
compared with that of MM-C 15min before
irradiation (P<0.005). For neither drug-radiation
interval did the Do change as compared to the Do for






Time (h) of drug injection
Figure 1 Effect of ADM given before, simultaneously with or after 8Gy. Each point is the mean value for
9-16 mice+se. All points have been reproduced at least once.
VOEi Radiation alone
V# ADM 8 mg kg 15 min before radiation
AO BLM 100 mg kg 1 15 min before radiation
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Figure 2 Survival curves for mouse jejunal crypt cells after radiation alone, after ADM 15min before
irradiation and after BLM either 15min or 2h before irradiation. Different symbols represent independent
experiments. The curves are based on the pooled data from independent, not significantly different
experiments. Each point is the mean value for 6 mice. Standard errors are indicated by bars except when
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Table I Survival curve characteristics for mouse jejunal crypt cells exposed to
radiation alone and in combination with cancer chemotherapeutic drugs.
Surviving
cells
Do D1o after IOGy
Treatment (Gy) (Gy) SClOGY DEFa IERb
Radiation alone 1.09 11.79 51.3
(1.01-1.17) (44.9-57.7)
ADM 15min 1.12 9.93 9.4 1.19 5.5
before radiation (0.98-1.26) (7.6-11.3)
BLM 15min 1.05 6.94 0.54 1.70 95
before radiation (0.91-1.19) (0.40-0.68)
BLM 2h 1.53 4.92 0.37 2.40 139
before radiation (1.41-1.65) (0.26-0.48)
MM-C 15min 1.07 10.25 12.6 1.15 4.1
before radiation (0.96-1.18) (10.4-14.9)
MM-C 6h 1.01 9.74 7.7 1.21 6.7
before radiation (0.87-1.15) (5.9-9.5)
Cis-DDP 15min 0.88 9.56 6.1 1.23 8.4
before radiation (0.79-0.97) (4.9-7.4)
Cis-DDP 1 h 0.90 9.70 7.1 1.22 7.2
before radiation (0.77-1.03) (5.1-9.1)
aDEF: Dose effect factor - D10 for radiation alone
D10 for radiation+drug
bIER: Isodose effect ratio = SCIOGY for radiation alone
SC10GY for radiation+drug
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Figure 3 Effect of BLM given before, simultaneously with or after 7Gy. Each point is the mean value for
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Time (h) of drug injection
Figure 4 Effect of MM-C given before, simultaneously with or after 9Gy. Each point is the mean value for
9-15 mice+se. All points have been reproduced at least once.
Cis-DDP and irradiation
As seen in Figure 5, cis-DDP enhanced the
radiation response only when given from 15min to
6h before irradiation and it had no effect if
administered after irradiation. Comparison of the
survival curve for drug administration 15min before
irradiation and the survival curve for radiation
alone showed that cis-DDP statistically significantly
displaced the curve to the left (P <0.001) and
decreased the Do (P <0.005). The DEF and IER
values were 1.23 and 8.4, respectively. Cis-DDP
administration 1 h before irradiation revealed
similar results with a statistically significantly
decreased Do (P<0.05). All data are summarized in
Table I.
Discussion
ADM combined with irradiation was found to
increase the regeneration time to 102h compared to
90h following radiation alone. The increased
regeneration time is probably due to an ADM-
induced delayed proliferation of the surviving cells
which corresponds to the observations made by
Burholt et al. (1975,1977). It has previously been
discussed that the assay time must be adjusted to
allow scoring of the crypt number at an equivalent
crypt size (von der Maase, 1984a; von der Maase &
Overgaard, 1983).
The present experiments were not specifically
designed to elucidate the basic mechanisms of drug-
radiation interactions. Therefore, hypotheses of
these mechanisms should be taken with great
caution. It is especially emphasized that suggestions
about interference with repair mechanisms can only
be conjectural as split-dose experiments have not
been carried out.
Administration of ADM from 24h before to 48h
after irradiation caused an almost constantly
increased cell kill, and the drug did not change the
Do for radiation alone. These observations indicate
that ADM and radiation may have an additive
effect. Similar results have been obtained by others
both using the crypt survival assay (Dethlefsen &
Riley, 1979; Moore & Broadbent, 1980; Ross et.,
1979), and the lethality assay (Dethlefsen & Riley,
1979; Schenken et al., 1976).
BLM had the most pronounced effect when
administered 2h before irradiation, the DEF and
IER values being 2.40 and 139, respectively.
However, at this interval as opposed to the 15min
interval, BLM surprisingly increased the Do for
radiation alone by a factor of 1.4 (Figure 2 and
Table I). Although indicators of an extreme
radiation-modifying effect, the DEF and IER values
therefore underestimate the interactions of BLM
and small radiation doses at this interval. If based
on the surviving cells after 2Gy instead of the
SC10GY' the IER would be 1.2 x 103. As BLM also
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Cis-DDP 6 mg kg 1 Cis-DDP 6 mg kg1
before 8 Gy after 8 Gy
8 Gy
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Time (h) of drug injection
Figure 5 Effect of cis-DDP given before, simultaneously with or after 8 Gy. Each point is the mean value for
9-18 mice+se. All points have been reproduced at least once.
lesser degree when given up to 24h after irradiation
(Figure 3), the combined effect was probably
additive or at least partly additive. Although the
number of crypts still was not restored 14 days after
treatment with BLM alone, the radiation response
was not enhanced at BLM administration 48 and
72h after irradiation (Figure 3). The reason may be
that the effect of BLM was not expressed when the
crypt number was evaluated (90h after irradiation).
As the effect of BLM was highly dependent on the
intervals and sequence of the combined treatment
(Figure 3), mechanisms other than a simple additive
one were obviously also present. The drop in the
crypt number at drug administration 12h after
irradiation may indicate a synchronization effect
and the extensive effect of BLM given 1-6h before
irradiation may be caused by radiation inhibition of
possible repair mechanisms of BLM-induced injury.
The increase in the Do at the 2h interval cannot be
accounted for with certainty although it may be
explained by an "overkill" at the largest radiation
doses in the combined treatment. A similarly
increased Do was observed for MTX administered
1 h before irradiation (von der Maase, 1984a) and
for large doses of ADM (15mgkg-') given
immediately after irradiation (Moore & Broadbent,
1980). Phillips et al. (1979) have reported results
very similar to the present ones with respect to the
dependence on the time schedule of BLM and
radiation treatment, but they failed to observe an
increased Do for BLM 2h before irradiation.
However, the survival curve for the BLM-radiation
combination was fitted to points embracing few
crypt cells per circumference (half of the points
below one crypt cell) which generally causes
estimation of the Do to become inaccurate.
The pattern of the combined effects of MM-C
and irradiation seen in Figure 4 may indicate that
the two modalities act both in an additive way and
by interference with repair mechanisms. The
diminishing effect of MM-C when administered
from a few hours before to 3 h after irradiation
(Figure 4) may indicate a drug-induced decreased
repair of sublethal radiation damage. The more
pronounced effect on administration 6h before
irradiation may possibly be explained by radiation
interference with repair of the effect of the drug. At
present, there are no other data concerning the
interactions of MM-C and irradiation in the
intestinal tract epithelium. MM-C has also been
shown to enhance the radiation induced skin
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The fact that cis-DDP enhanced the radiation
response only when given before irradiation and
decreased the Do for radiation alone may indicate a
true radiosensitization. This hypothesis has
previously been suggested in both in vivo and in
vitro studies (Douple & Richmond, 1978, 1979 and
1982; Overgaard & Khan, 1981; Richmond &
Powers, 1976; Richmond et al., 1977). A selective
enhancement at drug administration before
irradiation was also found using the mouse foot
skin scoring system (von der Maase, 1984b). Other
studies on the interactions of cis-DDP and
irradiation in the intestinal mucosa have confirmed
cis-DDP to have the most pronounced effect by
administration before irradiation (Burholt et al.,
1979; Luk et al., 1979; Schenken et al., 1979).
However, these studies also reported some degree of
enhancement by administration after irradiation
and suggested that the effect of cis-DDP was due to
a reduced repair of radiation injury.
As for the previously investigated combinations
of drugs and irradiation (von der Maase, 1984a),
the present study illustrates the complexity and
severity of drug-radiation interactions in the
intestinal tract epithelium. These observations
should serve to warn clinicians and should be taken
into consideration in the planning of combined
drug-radiation treatments of patients. On the basis
of the crypt survival data it seems that short
intervals between the two treatment modalities yield
the most serious injuries which for some
combinations were found to be dramatic.
Separation of drug and irradiation by days may
effectively spare the tissue and administration of
drugs before irradiation is likely to be more
damaging than administration after radiation
treatment. The results have, however, been based on
single-dose experiments and fractionated
experiments are obviously required to substantiate
our knowledge and understanding of clinically
relevant drug-radiation interactions. It is also
important to study late effects of the combined
treatments and much work therefore remains to be
done in this area.
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